Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M, Pöttgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, Metzenmacher M, Aigner C, Bölükbas S, Gauler T, Eberhardt WEE, Forsting M, Herrmann K, Theegarten D, Darwiche K, Jendrossek V, Stuschke M, Schuler M. Guberina M, et al. Among authors: eberhardt wee. Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174. Cancers (Basel). 2024. PMID: 38539510 Free PMC article.
Surgery in stage III non-small-cell lung cancer.
Eberhardt WE, Stamatis G, Stuschke M. Eberhardt WE, et al. Lancet. 2009 Aug 1;374(9687):359-60. doi: 10.1016/S0140-6736(09)61026-6. Epub 2009 Jul 24. Lancet. 2009. PMID: 19632715 No abstract available.
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J. Trarbach T, et al. Invest New Drugs. 2012 Oct;30(5):1962-71. doi: 10.1007/s10637-011-9754-x. Epub 2011 Oct 12. Invest New Drugs. 2012. PMID: 21989836 Clinical Trial.
Multimodal treatment of non-small-cell lung cancer.
Eberhardt WE, Stuschke M. Eberhardt WE, et al. Lancet. 2015 Sep 12;386(9998):1018-20. doi: 10.1016/S0140-6736(15)61083-2. Epub 2015 Aug 11. Lancet. 2015. PMID: 26275734 No abstract available.
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: eberhardt wee. J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27. J Thorac Oncol. 2017. PMID: 27575422 Free article.
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD. Walter RFH, et al. Among authors: eberhardt wee. J Oncol. 2018 Jul 17;2018:1986982. doi: 10.1155/2018/1986982. eCollection 2018. J Oncol. 2018. PMID: 30112000 Free PMC article.
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.
Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. Oezkan F, et al. Among authors: eberhardt wee. Clin Lung Cancer. 2018 Nov;19(6):e879-e884. doi: 10.1016/j.cllc.2018.08.016. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30206042
101 results